Question

Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...

Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April.

2018

  1. On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $14,000,000 at the bank’s prime rate (9.5% at the time). The company will pay no commitment fees.
  2. On October 1, borrowed $11 million cash from Second Commercial Bank under the line of credit and issued a five-month promissory note. Interest at the prime rate of 9% was payable at maturity. Management planned to issue 10-year bonds in February to repay the note.
  3. Received $2,300 of refundable deposits in December for reusable containers used to transport and store chemical-based products.
  4. For the September–December period, sales on account totaled $4,560,000. The state sales tax rate is 3% and the local sales tax rate is 3%. (This is a summary journal entry for the many individual sales transactions for the period.)
  5. Recorded the adjusting entry for accrued interest.


2019

  1. In February, issued $9.5 million of 10-year bonds at face value and paid the bank loan on the March 1 due date. f-2 Record the payment of the bank loan due on March 1.
  2. Half of the storage containers covered by refundable deposits were returned in March. The remaining containers are expected to be returned during the next six months.


Required:
1. Prepare the appropriate journal entries for 2018 and 2019 transactions.

0 0
Add a comment Improve this question Transcribed image text
Answer #1
Transaction General Journal Debit Credit
a. No journal entry required
b. Cash 11000000
Notes payable 11000000
(To record borrowing against note)
c. Cash 2300
Liability for refundable deposit 2300
(To record deposits collected)
d. Accounts receivable 4833600
Sales revenue 4560000
Sales tax payable ($4560000 x 6%) 273600
(To record sales on account)
e. Interest expense ($11000000 x 9% x 3/12) 247500
Interest payable 247500
(To record accrued interest on note)
f-1. Cash 9500000
Bonds payable 9500000
(To record issue of bonds)
f-2. Notes payable 11000000
Interest payable 247500
Interest expense ($11000000 x 9% x 2/12) 165000
Cash 11412500
(To record repayment of bank loan)
g. Liability for refundable deposit 1150
Cash ($2300 x 1/2) 1150
(To record deposits refunded)
Add a comment
Know the answer?
Add Answer to:
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Your Answer:

Post as a guest

Your Name:

What's your source?

Earn Coins

Coins can be redeemed for fabulous gifts.

Not the answer you're looking for? Ask your own homework help question. Our experts will answer your question WITHIN MINUTES for Free.
Similar Homework Help Questions
  • Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...

    Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $14,000,000 at the bank’s prime rate (9.5% at the time). The company will pay no commitment fees. On October 1, borrowed $11...

  • Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...

    Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $17,000,000 at the bank’s prime rate (12.5% at the time). The company will pay no commitment fees. On October 1, borrowed $14...

  • Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...

    Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019, Camden's fiscal year ends on December 31. Its financial statements are issued in April 2018 a. On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $9,000,000 at the bank's prime rate (12.5% at the time b. On October 1, borrowed $6 The company will pay no...

  • 2 Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of...

    2 Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden's fiscal year ends on December 31. Its financial statements are issued in April. 2018 a. On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $33,000,000 at the bank's prime rate (15.5% at the time). The company will pay no commitment fees. b. On October...

  • Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the...

    Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the company for September 2021 through March 2022. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2021 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $20,000,000 at the bank's prime rate (9.5% at the time). The company will pay no commitment fees. On October 1, borrowed $17...

  • Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the...

    Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the company for September 2021 through March 2022. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2021 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $17,000,000 at the bank's prime rate (12.5% at the time). The company will pay no commitment fees. On October 1, borrowed $14...

  • Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the...

    Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the company for September 2021 through March 2022. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2021 a. On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $27,000,000 at the bank's prime rate (12.5% at the time). The company will pay no commitment fees. b. On October 1,...

  • Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the...

    Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the company for September 2021 through March 2022 Camden's fiscal year ends on December 31. Its financial statements are issued in April. 2021 a On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $16,000,000 at the bank's prime rate (9.5% at the time). The company will pay no commitment fees. b. On October 1,...

  • Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the...

    Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the company for September 2021 through March 2022. Camden's fiscal year ends on December 31. Its financial statements are issued in April. 2021 a. On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $20,000,000 at the bank's prime rate (9.5% at the time). The company will pay no commitment fees. b. On October 1,...

  • Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the...

    Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the company for September 2021 through March 2022. Camden's fiscal year ends on December 31. Its financial statements are issued in April. 2021 a. On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $20,000,000 at the bank's prime rate (9.5% at the time). The company will pay no commitment fees. b. On October 1,...

ADVERTISEMENT
Free Homework Help App
Download From Google Play
Scan Your Homework
to Get Instant Free Answers
Need Online Homework Help?
Ask a Question
Get Answers For Free
Most questions answered within 3 hours.
ADVERTISEMENT
ADVERTISEMENT
Active Questions
ADVERTISEMENT